These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 1613737)

  • 1. Practice based evaluation of the longterm benefit of second line agents in rheumatoid arthritis.
    Paulus HE; Johnston KR; Lachenbruch PA
    J Rheumatol Suppl; 1992 Jan; 32():80-4. PubMed ID: 1613737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the progression of joint damage in rheumatoid arthritis.
    Scott DL; Farr M
    Drugs; 1986; 32 Suppl 1():63-70. PubMed ID: 2877856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The systematic study of drug therapy in rheumatoid arthritis.
    Johnson K
    J Rheumatol Suppl; 1990 Nov; 25():34-8. PubMed ID: 2273520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How do French rheumatologists treat early rheumatoid arthritis?
    de Asit N; Le Loët X; Czernichow P; Bertho JM; Delcambre B; Tonnel F; Loyau G; Dapogny C; Trèves R; Valat JP; Tauveron P; Sebert JL; Boumier P
    Rev Rhum Engl Ed; 1996 Mar; 63(3):188-95. PubMed ID: 8731236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From aspirin to biologics: therapeutic implications for rheumatoid arthritis.
    Wright V
    J Rheumatol Suppl; 1992 Jan; 32():95-7. PubMed ID: 1613740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Joint damage in rheumatoid arthritis: radiological assessments and the effects of anti-rheumatic drugs.
    Scott DL; Bacon PA
    Rheumatol Int; 1985; 5(5):193-9. PubMed ID: 3906844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenging the therapeutic pyramid: a new look at treatment strategies for rheumatoid arthritis.
    Wilske KR; Healey LA
    J Rheumatol Suppl; 1990 Nov; 25():4-7. PubMed ID: 2273521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term drug treatment of chronic polyarthritis: current status and perspectives].
    Wollenhaupt J; Langer HE
    Wien Med Wochenschr; 1990 Jun; 140(12):324-33. PubMed ID: 2204217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calculating radiological progression in rheumatoid arthritis.
    Scott DL; Dawes PT; Fowler PD; Shadforth MF
    Clin Rheumatol; 1986 Dec; 5(4):445-9. PubMed ID: 3816092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aggressive strategies for treating aggressive rheumatoid arthritis: has the case been proven?
    Furst DE
    Lancet; 2000 Jul; 356(9225):183-4. PubMed ID: 10963194
    [No Abstract]   [Full Text] [Related]  

  • 11. [Duration of use of non-steroidal anti-inflammatory agents in patients with rheumatoid arthritis].
    Luggen ME
    Rev Rhum Ed Fr; 1994 Dec; 61(10 Pt 2):165S-172S. PubMed ID: 7858568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methodology issues in the evaluation of NSAID in inflammatory rheumatic diseases.
    Lequesne M
    J Rheumatol Suppl; 1990 Feb; 20():25-8. PubMed ID: 2182853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Rheumatoid factors during controlled krizanol treatment of rheumatoid arthritis patients].
    Alekberova ZS; Trofimova TM; Speranskiĭ AI; Beresten' TI
    Revmatologiia (Mosk); 1985; (3):19-22. PubMed ID: 3903922
    [No Abstract]   [Full Text] [Related]  

  • 14. Other NSAIDs of choice for rheumatoid arthritis.
    Ehrlich GE
    Drug Intell Clin Pharm; 1984 Jan; 18(1):39-41. PubMed ID: 6607158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenging the pyramid. A new look at therapeutic approaches for rheumatoid arthritis. Earlier intervention with second line therapies.
    Ward JR
    J Rheumatol Suppl; 1990 Nov; 25():18-23. PubMed ID: 1980313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longterm treatment with nonsteroidal antiinflammatory drugs in rheumatoid arthritis: a prospective drug survival study.
    Wijnands M; van Riel P; van 't Hof M; Gribnau F; van de Putte L
    J Rheumatol; 1991 Feb; 18(2):184-7. PubMed ID: 2023212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The role of disease-modifying antirheumatic drugs (DMARDs) in the therapy of rheumatoid arthritis].
    Cervini C; Salaffi F; Peroni M
    Clin Ter; 1993 Jan; 142(1):3-18. PubMed ID: 8472508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modern treatment strategies in rheumatoid arthritis.
    Hetland ML
    Dan Med Bull; 2011 Nov; 58(11):B4320. PubMed ID: 22047935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are the results of controlled clinical trials and observational studies of second line therapy in rheumatoid arthritis valid and generalizable as measures of rheumatoid arthritis outcome: analysis of 122 studies.
    Hawley DJ; Wolfe F
    J Rheumatol; 1991 Jul; 18(7):1008-14. PubMed ID: 1920305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
    Fautrel B; Guillemin F; Meyer O; de Bandt M; Berthelot JM; Flipo RM; Lioté F; Maillefert JF; Wendling D; Saraux A; Combe B; Le Loët X; ; ;
    Arthritis Rheum; 2009 Apr; 61(4):425-34. PubMed ID: 19333993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.